Being analyzed from the immunophenoscore (IPS) distribution and external public immunotherapy database, an observed increase in the expression of programmed cell death 1 ligand 1 (PD-L1) driven by high expression of GBP5 endowed its potential role as a survival indicator for tumor patients receiving anti-PD1 and anti-PD-L1 therapy. The gene discussed is CD274; the disease is neoplasm.